Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 3, 2014-04 ,pp. : 447-451

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D   Wilding John PH  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

By Lamos Elizabeth M   Younk Lisa M   Davis Stephen N  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 6, 2014-06 ,pp. : 875-882

Informa Healthcare

Access to resources Recommend Favorite

Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

By  

Medicinal Chemistry, Vol. 10, Iss. 3, 2014-05 ,pp. : 304-317

Bentham Science Publishers

Access to resources Recommend Favorite

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

By Tanizawa Yukio   Kaku Kohei   Araki Eiichi   Tobe Kazuyuki   Terauchi Yasuo   Utsunomiya Kazunori   Iwamoto Yasuhiko   Watada Hirotaka   Ohtsuka Wataru   Watanabe Daisuke   Suganami Hideki  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 6, 2014-04 ,pp. : 749-766

Informa Healthcare

Access to resources Recommend Favorite